Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VHB 937

Next Previous
Drug Profile

VHB 937

Alternative Names: VHB-937

Latest Information Update: 08 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis; Novartis Institutes for BioMedical Research
  • Class Monoclonal antibodies
  • Mechanism of Action TREM2 protein-stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis

Most Recent Events

  • 30 Jul 2025 Novartis plans a phase II trial for Alzheimer's disease (IV, Infusion), in September 2025 (NCT07094516)
  • 06 Jul 2025 Phase-II clinical trials in Amyotrophic lateral sclerosis in United Kingdom, Switzerland, Sweden, Spain, Poland, Netherlands, South Korea, Japan, Ireland, Germany, France, Denmark, China, Canada, Belgium, Australia, USA (IV) (Novartis pipeline, July 2025)
  • 21 Oct 2024 Novartis Pharmaceuticals plans a phase II trial for Amyotrophic lateral sclerosis in October 2024 (NCT06643481) (EudraCT-2024-512536-29-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top